Sign in
  Edit search
Systemic treatment of psoriatic patients with bexarotene dec…
Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation%2C and improves differentiation in lesional skin.
Systemic treatment of psoriatic patients with bexarotene decreases epidermal proliferation and parameters for inflammation%2C and improves differentiation in lesional skin.
Article, Chapter
Authors: J.V. Smit
Publication: Journal of the American Academy of Dermatology, Volume:51, Issue:2, Page(s):-264
Published: Mosby, 2004
ISSN: 0190-9622
  Full text availability for this item
View Full Text Source:Journal of the American Academy of Dermatology,Journal of the American Academy of Dermatology,Elsevier ScienceDirect Journals Opens in new Window
Journal:  Journal of the American Academy of Dermatology Source:Elsevier ScienceDirect Journals Opens in new Window
Collection:  Elsevier ScienceDirect Journals Opens in new Window
Coverage:
  • 1979-07~present; volume:1~present;issue:1~present
Browse related articles
  Print copies at your library
Check availability in RUQuest
  Request a copy of this item
Cite this item